UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 1.372

Sortiert nach

Guidelines for the welfare and use of animals in cancer research

British journal of cancer, 2010-05, Vol.102 (11), p.1555-1577

2010

Link zum Volltext

Verfügbarkeit prüfen

Guidelines for preclinical and early phase clinical assessment of novel radiosensitisers

British journal of cancer, 2011-08, Vol.105 (5), p.628-639

2011

Link zum Volltext

Verfügbarkeit prüfen

HIF-1 and NF-κB-mediated upregulation of CXCR1 and CXCR2 expression promotes cell survival in hypoxic prostate cancer cells

Oncogene, 2007-11, Vol.26 (52), p.7333-7345

2007

Link zum Volltext

Verfügbarkeit prüfen

ZD1839 ('Iressa'), a specific oral epidermal growth factor receptor-tyrosine kinase inhibitor, potentiates radiotherapy in a human colorectal cancer xenograft model

British journal of cancer, 2002-04, Vol.86 (7), p.1157-1161

2002

Link zum Volltext

Verfügbarkeit prüfen

Anticancer chemosensitization and radiosensitization by the novel Poly(ADP-ribose) polymerase-1 inhibitor AG14361

JNCI : Journal of the National Cancer Institute, 2004-01, Vol.96 (1), p.56-67

2004

Link zum Volltext

Verfügbarkeit prüfen

Hypoxia-Inducible Factor-1 Modulates Gene Expression in Solid Tumors and Influences Both Angiogenesis and Tumor Growth

Proceedings of the National Academy of Sciences - PNAS, 1997-07, Vol.94 (15), p.8104-8109

1997

Link zum Volltext

Verfügbarkeit prüfen

Contribution of HIF-1 and drug penetrance to oxaliplatin resistance in hypoxic colorectal cancer cells

British journal of cancer, 2009-10, Vol.101 (8), p.1290-1297

2009

Link zum Volltext

Verfügbarkeit prüfen

Prognostic value of facilitative glucose transporter Glut-1 in oral squamous cell carcinomas treated by surgical resection: results of EORTC Translational Research Fund studies

European journal of cancer (1990), 2004-03, Vol.40 (4), p.503-507

2004

Link zum Volltext

Verfügbarkeit prüfen

Platelet-derived endothelial cell growth factor thymidine phosphorylase in tumour growth and response to therapy

British journal of cancer, 1997-09, Vol.76 (6), p.689-693

1997

Link zum Volltext

Verfügbarkeit prüfen

Imidazoacridin-6-ones as novel inhibitors of the quinone oxidoreductase NQO2

Bioorganic & medicinal chemistry letters, 2010-05, Vol.20 (9), p.2832-2836

2010

Link zum Volltext

Verfügbarkeit prüfen

The hypoxia-selective cytotoxin NLCQ-1 (NSC 709257) controls metastatic disease when used as an adjuvant to radiotherapy

British journal of cancer, 2010-07, Vol.103 (2), p.201-208

2010

Link zum Volltext

Verfügbarkeit prüfen

Inhibition of vascular endothelial growth factor signalling using cediranib (RECENTIN™; AZD2171) enhances radiation response and causes substantial physiological changes in lung tumour xenografts

British journal of radiology, 2008-10, Vol.81 (special_issue_1), p.S21-S27

2008

Link zum Volltext

Verfügbarkeit prüfen

Enhancement of chemotherapy and radiotherapy of murine tumours by AQ4N, a bioreductively activated anti-tumour agent

British journal of cancer, 2000-06, Vol.82 (12), p.1984-1990

2000

Link zum Volltext

Verfügbarkeit prüfen

Oxygen-sensitive enzyme-prodrug gene therapy for the eradication of radiation-resistant solid tumours

Gene therapy, 2002-07, Vol.9 (14), p.946-954

2002

Link zum Volltext

Verfügbarkeit prüfen

PCAF is an HIF-1α cofactor that regulates p53 transcriptional activity in hypoxia

Oncogene, 2008-10, Vol.27 (44), p.5785-5796

2008

Link zum Volltext

Verfügbarkeit prüfen

The experimental development of bioreductive drugs and their role in cancer therapy

Cancer and metastasis reviews, 1993-06, Vol.12 (2), p.73-82

1993

Link zum Volltext

Verfügbarkeit prüfen

The influence of oxygen tension and pH on the expression of platelet-derived endothelial cell growth factor/thymidine phosphorylase in human breast tumor cells grown in vitro and in vivo

Cancer research (Chicago, Ill.), 1997-02, Vol.57 (4), p.570-572

1997

Link zum Volltext

Verfügbarkeit prüfen

Hypoxia-Mediated Down-Regulation of Bid and Bax in Tumors Occurs via Hypoxia-Inducible Factor 1-Dependent and -Independent Mechanisms and Contributes to Drug Resistance

Molecular and Cellular Biology, 2004-04, Vol.24 (7), p.2875-2889

2004

Link zum Volltext

Verfügbarkeit prüfen

Hypoxia-regulated glucose transporter Glut-1 may influence chemosensitivity to some alkylating agents: results of EORTC (First Translational Award) study of the relevance of tumour hypoxia to the outcome of chemotherapy in human tumour-derived xenografts

International journal of oncology, 2005-06, Vol.26 (6), p.1477

2005

Link zum Volltext

Verfügbarkeit prüfen

Expression of the proapoptotic protein Bid is an adverse prognostic factor for radiotherapy outcome in carcinoma of the cervix

British journal of cancer, 2005-02, Vol.92 (3), p.449-458

2005

Link zum Volltext

Verfügbarkeit prüfen

Increased sensitivity to the prodrug 5'-deoxy-5-fluorouridine and modulation of 5-fluoro-2'-deoxyuridine sensitivity in MCF-7 cells transfected with thymidine phosphorylase

British journal of cancer, 1995-09, Vol.72 (3), p.669-675

1995

Link zum Volltext

Verfügbarkeit prüfen

Nitric oxide synthases catalyze the activation of redox cycling and bioreductive anticancer agents

Cancer research (Chicago, Ill.), 1999-04, Vol.59 (8), p.1929-1934

1999

Link zum Volltext

Verfügbarkeit prüfen

No relationship between thymidine phosphorylase (TP, PD-ECGF) expression and hypoxia in carcinoma of the cervix

British journal of cancer, 2006-01, Vol.94 (1), p.115-120

2006

Link zum Volltext

Verfügbarkeit prüfen

Emerging Opportunities for the Combination of Molecularly Targeted Drugs with Radiotherapy

Clinical oncology (Royal College of Radiologists (Great Britain)), 2014-05, Vol.26 (5), p.266-276

2014

Link zum Volltext

Verfügbarkeit prüfen

Identification of a novel class of inhibitor of human and Escherichia coli thymidine phosphorylase by in silico screening

Bioorganic & medicinal chemistry letters, 2003-11, Vol.13 (21), p.3705-3709

2003

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 1.372

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(1.237)
Mit Volltextzugriff
(1.220)

Publikationsform

4 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(843)
Life Sciences & Biomedicine
(683)
Humans
(464)
Animals
(360)
Biological And Medical Sciences
(342)
Female
(243)
Medical Sciences
(241)
Male
(214)
Oncology
(214)
Mice
(170)
Pharmacology. Drug Treatments
(127)
Middle Aged
(118)
Fundamental And Applied Biological Sciences. Psychology
(115)
Adult
(110)
Physical Sciences
(107)
Pharmacology & Pharmacy
(106)
Antineoplastic Agents
(100)
Technology
(98)
Aged
(85)
Tumors
(82)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Guidelines for the welfare and use of animals in cancer research

Guidelines for preclinical and early phase clinical assessment of novel radiosensitisers

HIF-1 and NF-κB-mediated upregulation of CXCR1 and CXCR2 expression promotes cell survival in hypoxic prostate cancer cells

ZD1839 ('Iressa'), a specific oral epidermal growth factor receptor-tyrosine kinase inhibitor, potentiates radiotherapy in a human colorectal cancer xenograft model

Anticancer chemosensitization and radiosensitization by the novel Poly(ADP-ribose) polymerase-1 inhibitor AG14361

Hypoxia-Inducible Factor-1 Modulates Gene Expression in Solid Tumors and Influences Both Angiogenesis and Tumor Growth

Contribution of HIF-1 and drug penetrance to oxaliplatin resistance in hypoxic colorectal cancer cells

Prognostic value of facilitative glucose transporter Glut-1 in oral squamous cell carcinomas treated by surgical resection: results of EORTC Translational Research Fund studies

Platelet-derived endothelial cell growth factor thymidine phosphorylase in tumour growth and response to therapy

Imidazoacridin-6-ones as novel inhibitors of the quinone oxidoreductase NQO2

The hypoxia-selective cytotoxin NLCQ-1 (NSC 709257) controls metastatic disease when used as an adjuvant to radiotherapy

Inhibition of vascular endothelial growth factor signalling using cediranib (RECENTIN™; AZD2171) enhances radiation response and causes substantial physiological changes in lung tumour xenografts

Enhancement of chemotherapy and radiotherapy of murine tumours by AQ4N, a bioreductively activated anti-tumour agent

Oxygen-sensitive enzyme-prodrug gene therapy for the eradication of radiation-resistant solid tumours

PCAF is an HIF-1α cofactor that regulates p53 transcriptional activity in hypoxia

The experimental development of bioreductive drugs and their role in cancer therapy

The influence of oxygen tension and pH on the expression of platelet-derived endothelial cell growth factor/thymidine phosphorylase in human breast tumor cells grown in vitro and in vivo

Hypoxia-Mediated Down-Regulation of Bid and Bax in Tumors Occurs via Hypoxia-Inducible Factor 1-Dependent and -Independent Mechanisms and Contributes to Drug Resistance

Hypoxia-regulated glucose transporter Glut-1 may influence chemosensitivity to some alkylating agents: results of EORTC (First Translational Award) study of the relevance of tumour hypoxia to the outcome of chemotherapy in human tumour-derived xenografts

Expression of the proapoptotic protein Bid is an adverse prognostic factor for radiotherapy outcome in carcinoma of the cervix

Increased sensitivity to the prodrug 5'-deoxy-5-fluorouridine and modulation of 5-fluoro-2'-deoxyuridine sensitivity in MCF-7 cells transfected with thymidine phosphorylase

Nitric oxide synthases catalyze the activation of redox cycling and bioreductive anticancer agents

No relationship between thymidine phosphorylase (TP, PD-ECGF) expression and hypoxia in carcinoma of the cervix

Emerging Opportunities for the Combination of Molecularly Targeted Drugs with Radiotherapy

Identification of a novel class of inhibitor of human and Escherichia coli thymidine phosphorylase by in silico screening

Suchergebnisse filtern